Abstract
Mycobacterium tuberculosis (Mtb) continues to be a threat to Global Public Health, and its control will require an array of therapeutic strategies. It has been appreciated that high-throughput screens using cell-based assays to identify compounds targeting Mtb within macrophages represent a valuable tool for drug discovery. However, the host immune environment, in the form of lymphocytes and cytokines, is completely absent in a chemical screening platform based on infected macrophages alone. The absence of these players unnecessarily limits the breadth of novel host target pathways to be interrogated. In this study, we detail a new drug screening platform based on dissociated murine TB granulomas, named the Deconstructed Granuloma (DGr), that utilizes fluorescent Mtb reporter strains screened in the host immune environment of the infection site. The platform has been used to screen a collection of known drug candidates. Data from a representative 384-well plate containing known anti-bacterial compounds are shown, illustrating the robustness of the screening platform. The novel deconstructed granuloma platform represents an accessible, sensitive and robust high-throughput screen suitable for the inclusive interrogation of immune...Continue Reading
References
May 1, 1997·Antimicrobial Agents and Chemotherapy·L Collins, S G Franzblau
Sep 19, 2000·Antimicrobial Agents and Chemotherapy·N RastogiA Bryskier
Apr 7, 2004·The Biochemical Journal·Satoshi KarasawaAtsushi Miyawaki
Aug 15, 2006·Current Opinion in Pharmacology·Khisimuzi Mdluli, Melvin Spigelman
Mar 8, 2007·Nature Medicine·Ann M Ginsberg, Melvin Spigelman
Oct 27, 2010·Nature Communications·Kevin PetheThomas Dick
Jan 29, 2011·Nature·Anil KoulKoen Andries
Mar 24, 2011·Future Medicinal Chemistry·Thierry ChristophePriscille Brodin
Aug 13, 2011·Current Pharmaceutical Design·A D PrangerR E Aarnoutse
Sep 10, 2011·Frontiers in Microbiology·Gyanu Lamichhane
May 15, 2012·ACS Chemical Biology·Sarah A StanleyDeborah T Hung
Sep 18, 2012·Cell Host & Microbe·Constance J MartinSamuel M Behar
Apr 18, 2013·PLoS Pathogens·Shumin TanDavid G Russell
Oct 29, 2014·Antimicrobial Agents and Chemotherapy·Mayra Silva-MirandaFrédéric Altare
Dec 3, 2014·Seminars in Immunology·Kevin B Urdahl
Jan 23, 2015·Innate Immunity·Jodi F HedgesMark A Jutila
Feb 13, 2015·PLoS Pathogens·Brian C VanderVenDavid G Russell
Feb 18, 2015·Future Microbiology·Edison S ZunigaTanya Parish
Mar 31, 2016·Microbiology·Jacoba M MoutonSamantha L Sampson
Apr 27, 2016·The Journal of Experimental Medicine·Yancheng LiuDavid G Russell
Jun 2, 2017·Nature·David G Russell
Jul 8, 2017·Journal of Microbiology and Biotechnology·Ye-Ram Kim, Chul-Su Yang
Aug 22, 2017·Current Opinion in Immunology·Lu Huang, David G Russell
Sep 25, 2017·Nature Reviews. Drug Discovery·Stefan H E KaufmannRalf Bartenschlager
Nov 3, 2017·Frontiers in Medicine·Afsal Kolloli, Selvakumar Subbian
Nov 28, 2017·Frontiers in Microbiology·Rashmi GuptaKyle H Rohde
Mar 4, 2018·The Journal of Experimental Medicine·Lu HuangDavid G Russell
Citations
Jun 25, 2019·Cellular Microbiology·David G Russell
Sep 11, 2019·Annual Review of Microbiology·Bridget GollanSophie Helaine
Dec 7, 2018·Nature Methods·Mark R CronanDavid M Tobin
Jan 5, 2020·Expert Opinion on Drug Discovery·Tanya Parish
Dec 8, 2020·Frontiers in Cellular and Infection Microbiology·Melissa D ChengalroyenValerie Mizrahi
Feb 6, 2021·Metabolites·Dorothy Pei Shan Chang, Xue Li Guan
Feb 18, 2020·Drug Discovery Today·Stanislav HuszárVinayak Singh
Apr 3, 2021·Frontiers in Cellular and Infection Microbiology·Hee-Jeong YangLaura E Via
Apr 5, 2021·Cellular Microbiology·Neeraja Subhash, Varadharajan Sundaramurthy
Jul 29, 2021·PLoS Biology·Richard C LavinShumin Tan
Jul 7, 2021·Antimicrobial Agents and Chemotherapy·Oluwaseun EgbelowoVéronique Dartois
Sep 3, 2021·Biomolecular Concepts·Shilpaa MukundanBiju Parekkadan